Flagship Harbor Advisors LLC increased its stake in Merck & Company, Inc. (NYSE:MRK) by 21.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,246 shares of the company’s stock after buying an additional 4,075 shares during the period. Flagship Harbor Advisors LLC’s holdings in Merck & were worth $1,478,000 as of its most recent filing with the SEC.

Several other hedge funds also recently added to or reduced their stakes in the company. Vigilant Capital Management LLC increased its stake in Merck & by 16.7% in the first quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock valued at $111,000 after buying an additional 250 shares during the period. Gradient Investments LLC increased its stake in Merck & by 41.3% in the first quarter. Gradient Investments LLC now owns 2,306 shares of the company’s stock valued at $147,000 after buying an additional 674 shares during the period. Pinnacle Bank bought a new stake in Merck & during the first quarter valued at about $152,000. Tortoise Investment Management LLC increased its stake in Merck & by 50.6% in the fourth quarter. Tortoise Investment Management LLC now owns 2,678 shares of the company’s stock valued at $158,000 after buying an additional 900 shares during the period. Finally, Thomas J. Herzfeld Advisors Inc. bought a new stake in Merck & during the fourth quarter valued at about $159,000. Institutional investors own 73.73% of the company’s stock.

Shares of Merck & Company, Inc. (NYSE MRK) traded up 0.32% during trading on Friday, hitting $62.38. The stock had a trading volume of 6,050,985 shares. The stock’s 50-day moving average is $63.36 and its 200-day moving average is $63.80. The stock has a market capitalization of $170.13 billion, a P/E ratio of 33.77 and a beta of 0.80. Merck & Company, Inc. has a 12-month low of $58.29 and a 12-month high of $66.80.

Merck & (NYSE:MRK) last issued its quarterly earnings results on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $0.14. The business had revenue of $9.93 billion during the quarter, compared to analysts’ expectations of $9.75 billion. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.93 earnings per share. Analysts predict that Merck & Company, Inc. will post $3.87 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, October 6th. Investors of record on Friday, September 15th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 3.01%. The ex-dividend date of this dividend is Thursday, September 14th. Merck &’s dividend payout ratio (DPR) is currently 76.11%.

TRADEMARK VIOLATION NOTICE: This article was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.dailypolitical.com/2017/08/13/merck-company-inc-mrk-stake-boosted-by-flagship-harbor-advisors-llc.html.

Several brokerages recently weighed in on MRK. Credit Suisse Group set a $72.00 target price on Merck & and gave the company a “buy” rating in a research note on Tuesday, June 6th. BidaskClub downgraded Merck & from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. BMO Capital Markets restated an “outperform” rating and set a $70.00 target price on shares of Merck & in a research note on Sunday, April 23rd. Vetr downgraded Merck & from a “strong-buy” rating to a “buy” rating and set a $69.99 target price for the company. in a research note on Wednesday, May 17th. Finally, Zacks Investment Research upgraded Merck & from a “hold” rating to a “buy” rating and set a $72.00 target price for the company in a research note on Wednesday, May 10th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $69.58.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.